5 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Clinical Studies on a Multivalent Vaccine for Human Visceral Leishmaniasis (MuLeVaClin)
Date du début: 1 nov. 2013, Date de fin: 31 oct. 2018,
The World Health Organisation in its report on Neglected Tropical Diseases has stated that there is overwhelming evidence to show that the burden caused by many of the 17 diseases that affect more than 1billion people worldwide can be effectively controlled and, in many cases, eliminated or even eradicated. Leishmaniasis caused by Leishmania spp is one of them and poses a grave health risk to an e ...
Voir le projet
9
Participants partenaires
TERMINÉ
A “Universal” Influenza Vaccine through Synthetic, Dendritic Cell-Targeted, Self-Replicating RNA Vaccines (UniVax)
Date du début: 1 oct. 2013, Date de fin: 30 sept. 2018,
Although vaccination is the cornerstone of prophylaxis, current vaccines provide only moderate protection. Most employ inactivated or protein-based, including multimeric antigen, vaccines requiring annual updating. Their limited antigen loads provide limited capacity for inducing robust immune defences, without assurance that both humoral and cell mediated (CMI) responses, as well as durable immun ...
Voir le projet
11
Participants partenaires
TERMINÉ
Novel Bone Morphogenetic Protein-6 Biocompatible Carrier Device for Bone Regeneration (OSTEOGROW)
Date du début: 1 janv. 2012, Date de fin: 31 déc. 2016,
Goals: We will carry out a regenerative medicine clinical trial of the therapeutic system OSTEOGROW for regenerating bone through harnessing a novel bone regenerative product to accelerate and enhance bone repair.The osteogenic regenerative product is composed of an autologous carrier and a biologically active recombinant human protein offering a therapeutic solution in bone regeneration superior ...
Voir le projet
11
Participants partenaires
TERMINÉ
Microbicide Optimization Through Innovative Formulation for Vaginal and Rectal Delivery (MOTIF)
Date du début: 1 oct. 2012, Date de fin: 31 mars 2016,
"The 40% protection against HIV-1 infection with vaginally-applied tenofovir gel demonstrated in the CAPRISA004 trial, has emphasized development of anti-retroviral (ARV)-based microbicides. Combining ARVs in a single product may provide increased protection. Development of a generally applicable formulation platform for combining ARVs (even if chemically incompatible) and understanding of the pro ...
Voir le projet
9
Participants partenaires
TERMINÉ
Development of an oral Helicobacter Pylori vaccine (HELICOVAXOR)
Date du début: 1 oct. 2012, Date de fin: 31 déc. 2014,
"Helicobacter pylori infection is highly prevalent worldwide and is an important cause of gastritis, peptic ulcer disease, and significantly gastric cancer. Because eradication requires treatment with multidrug regimens, there exists a very strong need for a vaccine to prevent initial infection.Immunization with H pylori protein subunits in humans has shown adjuvant-related adverse effects and onl ...
Voir le projet